MarkADicksonMD

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Dickson

Dr. Mark Dickson is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 14 years. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(830) 319-3929

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2020 - 2025
NY State Medical License 2010 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Clinical Trials

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Start of enrollment: 2008 May 14
Completed
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Start of enrollment: 2010 Aug 01
Completed
Phase 1, Phase 2
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Start of enrollment: 2010 Sep 23
Completed
Phase 2

Publications & Presentations

PubMed

71 citations
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian A. Van Tine
Journal of Clinical Oncology. 2021-10-12
23 citations
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
Evan Rosenbaum, Ciara Marie Kelly, Sandra P. D'Angelo, Mark A. Dickson, Mrinal M. Gounder
The Oncologist. 2019-10-01
102 citations
Liposarcoma: Multimodality Management and Future Targeted Therapies
Aimee M. Crago, Mark A. Dickson
Surgical Oncology Clinics of North America. 2016-10-01

Journal Articles

TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated Liposarcoma
Mark A Dickson, Edwin Choy, Nature

Lectures

Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Big, Fat Tumors: Liposarcomas Can Top 70 PoundsOctober 5th, 2018